Navigation Links
Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
Date:1/6/2009

Lead candidate on track for IND submission first half of 2009.

SAN DIEGO, Jan. 6 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced AM211, Amira's internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway, is on target for submission of an IND to the U.S. Food and Drug Administration (FDA) by mid-2009 following the successful completion of Good Laboratory Practices (GLP) toxicity studies.

AM211 is an oral, selective antagonist of the receptor DP2 (also known as CRTH2 or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes). DP2 is a high affinity receptor for prostaglandin (PG) D2 and, in humans, is implicated in Th2-dependent allergic inflammation. Recent studies have shown that a DP2 antagonist has the potential to be an oral treatment for asthma, Chronic Obstructive Pulmonary Disease (COPD) and allergic rhinitis.

"Our pre-clinical studies demonstrate that a low dose of AM211 is effective in several inflammatory/allergic models," said Peppi Prasit, PhD, Chief Scientific Officer, Amira. "Based on the pharmacokinetics and pharmacodynamics in preclinical models and its safety profile, we believe that AM211 has the potential to be an exciting next generation, once a day oral medication for respiratory diseases including COPD. In addition, we have a structurally distinct backup compound, AM461, about to enter GLP toxicity studies."

"Amira is establishing a track record of rapid and efficient discovery and early drug development. For the second time in as many programs, Amira is on track to enter human studies within two years from program start," said Bob Baltera, Amira's Chief Executive Officer. "These are exciting times at Amira as our team continues to demonstrate world-class capabilities in drug discovery and development."

About Amira

Founde
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
2. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
3. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
4. Amira Pharmaceuticals Appoints First Vice President of Development
5. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
6. American Asthma Foundation Announces Breakthrough Discovery
7. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
8. WellPoint Announces Innovative Program to Help Improve the Care of Members Suffering With Bipolar Disorder
9. DiFUSION Technologies Announces Company Launch Focused on Surgical Site Infections (SSIs)
10. FASgen, Inc. Announces Research and License Agreement With Centocor, Inc.
11. B2B Marketing Pro Toby Younis Announces Free Webcast on "BuzzMaking"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 Super Saturday, the last Saturday ... as the busiest day in the 2014 holiday shopping ... Station had a steady pre-Christmas stream of customers, ready ... Saturday. , “I definitely intend to take advantage…of the ... resident who was enjoying The Grass Station’s holiday sale ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Give a ... season, the gift of health and vitality. , For ... its three top-selling anti-aging formulas in special Holiday Wellness ... rush delivery. , Each bottle contains cutting-edge, proven ... that don't work as well as we age. ...
(Date:12/22/2014)... December 22, 2014 Pasadena sleep ... consultations for sleep apnea. Drowsy drivers are 15 times ... who are well-rested, and some experts believe that sleep-deprived ... as intoxicated drivers. Unfortunately, millions of Americans may be ... Academy of Sleep Medicine, about 18 million Americans have ...
(Date:12/22/2014)... TheHardwareCity.com now stocks MagnoGrip Pro Utility Magnetic ... Customers of the large online tool shop enjoy a ... to their home or workplace with free shipping. , ... heavy duty magnets, which make work easier. The patented ... metal parts on the back of their hand, including ...
(Date:12/22/2014)... NAPW honors Michelle M. ... Year. Ms. Foley is recognized with this prestigious distinction ... organization of professional women in the country, spanning virtually ... Women is a powerfully vibrant networking community with over ... a nurse, I felt like I made a difference ...
Breaking Medicine News(10 mins):Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2
... Jan. 27 Hooper Holmes (Amex: HH ... as Senior Vice President, General Counsel and Corporate Secretary. ... of Hooper Holmes, Inc.Mr. Rosenblum has over 23 years ... including intellectual property, securities, contract, consumer and other class ...
... Net Product Sales Increased 9% Over 2007 to $765.3 ... 2010SAN DIEGO, Calif., Jan. 27 Amylin Pharmaceuticals, Inc. ... for the quarter and year ended December 31, 2008. ... the quarter ended December 31, 2008, which includes net ...
... Systems, Inc. (NASDAQ: MRCY ), a leading ... complex image, sensor, and signal processing applications, announced that ... sale of its wholly-owned subsidiaries, Visage Imaging(R), Inc. and ... Limited. The financial terms of the transaction were not ...
... to Public OpinionWASHINGTON, Jan. 27 Political considerations ... from President Obama,s huge economic stimulus package, despite ... their high level of public approval.A recent Lake ... Women Donors Network in early November 2008 around ...
... could help treat depression, other disorders, researchers say , , ... scientists say they,ve devised a potential new method ... the natural dynamics of the body,s "fight or flight" ... adrenal (HPA) axis, one of the body,s major control ...
... just watching symptoms leads to similar survival rates in ... Using the biomarker molecule known as brain natriuretic peptide ... heart failure did not improve the clinical outcome in ... been conflicting reports about the value of monitoring blood ...
Cached Medicine News:Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 2Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 3Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 2Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 3Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 4Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 5Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 6Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 7Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 8Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 9Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 10Health News:Mercury Computer Systems Announces the Sale of Visage Imaging to Pro Medicus Limited 2Health News:Mercury Computer Systems Announces the Sale of Visage Imaging to Pro Medicus Limited 3Health News:Mercury Computer Systems Announces the Sale of Visage Imaging to Pro Medicus Limited 4Health News:Family Planning Again Becomes Political Football 2Health News:Family Planning Again Becomes Political Football 3Health News:Monitoring Protein Didn't Improve Heart Failure Outcomes 2Health News:Monitoring Protein Didn't Improve Heart Failure Outcomes 3
(Date:12/22/2014)... NEW YORK , Dec. 22, 2014 /PRNewswire/ ... developing novel therapies for the treatment of chronic ... subjects has been dosed in a pharmacokinetic and ... receptor antagonist for neuropathic pain. Racemic ... treatment of various pain states and substitution therapy ...
(Date:12/19/2014)... 2014 TODAY, AEGATE, the leader ... announced the appointment of Peter Fox as ... Channels and Partner Officer. Peter has served ... its acquisition by Oracle in 2011. Prior ... Geneva and subsequently Convergys, a world renowned ...
(Date:12/19/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB:  ... in the development of brachytherapy devices and medical ... that a Life Sciences Discovery Fund (LSDF) Proof ... AMIC is the commercialization partner.  The award was ... proposal titled "Optimized Injectable Radiogels for High-dose Therapy ...
Breaking Medicine Technology:Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
... Schering-Plough Corporation,(NYSE: SGP ) today reported that ... Phase II study of boceprevir, its investigational oral ... chronic,hepatitis C virus (HCV) genotype 1 were presented ... for the Study of the Liver (EASL). The,ongoing ...
... Into New Promising Drugs to Combat Hepatitis ... C ... Stem Cells of Potential Benefit in Liver Transplantation, ... At today,s sessions of the 43rd Annual Meeting of the European,Association for the ...
Cached Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
The Storz Protege is an anterior segment unit only....
The CV-12000 provides the surgeon with all the options to perform today's newest techniques....
Phaco-emulsification systems CV series...
The unprecedented power, flexibility and versatility of the Series 20000 Legacy have made it the world's leading phacoemulsifier....
Medicine Products: